(PDF) P2.01-109 Treatment Duration—A More Reasonable

P2.01-109 Treatment Duration—A More Reasonable Definition to Evaluate the Efficacy of Crizotinib in ALK Positive Advanced NSCLC

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1164

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient

Molecular and Clinical Oncology

Cancer Research

English

Efficacy of Target Therapy With Crizotinib in a Patient With Alk-Positive Advanced Gastric Cancer

Siberian Journal of Oncology

Cancer Research

English

P1.01-39 Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study

Journal of Thoracic Oncology

Respiratory Medicine

English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology

Cancer Research

English

P2.01-89 Synergistic Cytotoxicity Through MAPK/ERK Pathway and ALK Inhibition in Crizotinib Resistant EML4-ALK-Positive Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P115 Clinical Outcome of Crizotinib in Diverse ALK Fusion Partners and Different Detection Methods Treatment Naïve Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

Alectinib Provides a New Option for ALK-positive NSCLC Patients After Progression on Crizotinib

Journal of Community and Supportive Oncology

English

P2.13-05 Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients With Advanced ALK-Positive NSCLC.

Journal of Thoracic Oncology

Respiratory Medicine

English

Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

Multidisciplinary

English